Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Ann Coloproctol > Volume 42(4); 2026 > Article
Original Article
Anorectal physiology & pelvic floor disorder
Feasibility and preliminary outcomes of spinal magnetic stimulation for functional constipation: a pilot randomized placebo-controlled trial
Terence Si Quan Lee1orcid, Kai Xun Yew2orcid, Yew Long Lo3orcid, Peggy Pei Chee Teng3orcid, Yam Eng Tan3orcid, Emile John Kwong Wei Tan1orcid
Annals of Coloproctology 2026;42(4):415-424.
DOI: https://doi.org/10.3393/ac.2025.01599.0228
Published online: August 25, 2026

1Department of Colorectal Surgery, Singapore General Hospital, Singapore

2Group Finance Analytics, SingHealth, Singapore Health Services, Singapore

3Department of Neurology (SGH Campus), National Neuroscience Institute, Singapore

Correspondence to: Emile John Kwong Wei Tan, MBBS, MD Department of Colorectal Surgery, Singapore General Hospital, 20 College Rd, Singapore 169856 Email: emile.john.tan.k.w@singhealth.com.sg
• Received: December 29, 2025   • Revised: February 9, 2026   • Accepted: March 12, 2026

© 2026 The Korean Society of Coloproctology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 1,277 Views
  • 32 Download
  • Purpose
    Patients with chronic functional constipation suffer from debilitating symptoms which are unresponsive to conventional treatment options. Spinal magnetic stimulation (SMS) and its extracorporeal stimulation of peripheral nerves offer a potential noninvasive therapeutic option.
  • Methods
    A pilot blinded randomized sham-controlled study was performed. Patients randomized to the treatment SMS-arm underwent daily 60-minute SMS sessions at T9 and L3 spinal processes for 2 weeks. Symptom relief was measured at regular intervals up to 14 weeks after treatment with the use of constipation and quality-of-life questionnaires (Patient Assessment of Constipation Symptoms [PAC-SYM], EuroQOL 5-dimension instrument [EQ-5D], and Hospital Anxiety and Depression Scale [HADS]).
  • Results
    From December 2015 to July 2023, 14 patients completed the study (6 in the SMS arm and 8 in the sham arm). Mean age was 55 years (range, 41–70 years), and 12 (85.7%) were male. Median average bowel movements per week and spontaneous bowel movements per week at baseline for the SMS arm was 1.5 and 0.3, respectively, while the sham arm was 4 and 1, respectively. At 14 weeks from start of treatment, SMS arm patients showed a trend in improvement of symptoms in 11 out of 16 questions of PAC-SYM. Average bowel movements per week and EQ-5D health state scores increased from 1.5 to 3 and 50 to 60, respectively. However, these changes did not reach statistical significance. No statistical difference in the symptoms was noted in PAC-SYM (13 questions at weeks 1, 2, 4, 6, 8, 10, 12, and 14), EQ-5D (5 questions at weeks 0, 2, 14), and HADS (14 questions at weeks 0, 2, and 14) questionnaires within both arms.
  • Conclusion
    The pilot study showed the use of SMS is safe and feasible. While it improved constipation symptoms, the results did not achieve statistical significance possibly related to insufficient participants.
Chronic functional constipation is a common gastrointestinal disorder, affecting up to 15% of the population worldwide [1]. It is characterized by infrequent bowel movements, hard stool consistency, excessive straining, and a persistent sensation of incomplete evacuation. The mainstays of management include lifestyle changes, dietary modification, and laxative use [2, 3]. However, a substantial subset of patients remains refractory to these conventional treatment strategies. These patients often experience debilitating symptoms and impaired quality of life, and impose a significant burden on healthcare systems [4].
For patients whose symptoms are resistant to conventional treatment, additional options include specialized pharmacological agents, biofeedback, and surgery [2, 3, 5, 6]. However, these approaches have variable success rates and are often limited by factors such as adverse effects, invasiveness, or accessibility.
The use of neuromodulation as a treatment modality for functional constipation dates back to the early 2000s, when studies described the use of sacral nerve stimulation (SNS) for constipation, with mixed success [7–10]. Stimulation of the sacral nerves modulates reflex pathways and may improve anorectal sensory and motor function as well as colonic wave sequences [9, 11]. Nonetheless, a major drawback of SNS is the need for electrode implantation to directly stimulate peripheral nerves.
In contrast to SNS, magnetic stimulation offers a noninvasive approach to peripheral nerve stimulation. Its applications in the management of refractory functional constipation have received increasing interest, with transcranial, transabdominal, and spinal magnetic stimulation (SMS) approaches having been reported [12–17]. Magnetic stimulation is based on Faraday’s law, whereby a time-varying current creates a magnetic field that induces an electric current in nearby conductive tissues. When applied to peripheral nerves, this technique can activate and modulate neural activity [18–20]. Similar to SNS for constipation, SMS is hypothesized to modulate neurocircuits involved in gut motility and defecation. Physiological studies have demonstrated that SMS can enhance colonic motility, improve rectal sensation, and facilitate defecatory dynamics in patients with chronic constipation [17].
Initial studies of SMS have reported encouraging outcomes in selected patient groups with chronic constipation, including patients with Parkinson disease, those with prior spinal injury, and older adults [14, 16, 17, 21]. Reported benefits include improvements in colonic transit time, defecation frequency, and symptom relief. However, these studies were limited by their open-label design, which made them more susceptible to observer, performance, and detection bias.
In this study, we conducted a pilot randomized controlled trial to assess the potential efficacy of SMS in patients with chronic functional constipation. By improving our understanding of this novel modality, we aim to inform future noninvasive strategies for the management of refractory chronic functional constipation.
Ethics statement
This study was approved by the Institutional Review Board of Singapore General Hospital (No. 2015-2717). All patients provided informed consent prior to participation.
Study design and patient selection
The study was designed as a prospective, double-blind, randomized, sham-controlled trial. Patients aged 21–80 years were recruited from the functional and pelvic floor disorder clinics in the Departments of Colorectal Surgery and Gastroenterology at Singapore General Hospital. During their previous treatment course, all patients underwent multidisciplinary team evaluation by gastroenterologists, urogynecologists, colorectal surgeons, and specialist nurses. Before trial enrollment, suitability was assessed by 2 senior clinicians. Eligible patients were required to have a diagnosis of functional gastrointestinal dysfunction, as determined by the managing physician, and to fulfill the Rome III criteria for irritable bowel syndrome with constipation and functional constipation. Specifically, at least 2 of the following criteria had to be present during the last 3 months, with symptom onset at least 6 months before diagnosis: (1) straining during >25% of defecations; (2) lumpy or hard stools during >25% of defecations; (3) sensation of incomplete evacuation during >25% of defecations; (4) sensation of anorectal obstruction/blockage during >25% of defecations; (5) manual maneuvers during >25% of defecations; and (6) fewer than 3 defecations per week. In addition, loose stools were required to be rarely present in the absence of laxative use.
Criteria for refractory constipation included an average of fewer than three complete spontaneous bowel movements per week during the preceding 3 months and persistent symptoms for at least 1 year, defined as a Patient Assessment of Constipation Symptoms (PAC-SYM) score of at least moderate on any subscale, despite trials of two or more medical treatments, including dietary modification and laxatives, and/or other therapies such as biofeedback or previous pelvic floor surgery. Patients were also required to have undergone appropriate gastrointestinal or abdominal investigations to exclude significant structural abnormalities that could account for their symptoms. These investigations had to be performed within 24 months before enrolment, or within 60 months for colonoscopy, barium enema, or other colonic imaging, with the absence of a significant structural abnormality confirmed by the primary physician. Regular medications for constipation were permitted provided the dose had remained stable for at least 3 months before enrolment.
Exclusion criteria included relative contraindications to magnetic stimulation, such as cardiac pacemakers, metallic implants, or cardiac stents. Patients were also excluded if they were pregnant or breastfeeding, had a history of seizures, had uncontrolled hypertension, or were in poor physical condition for the procedure. In addition, patients with a new medication or a change in medication known to affect gastrointestinal motility within the previous 3 months were excluded.
Based on previous constipation trials [22], we assumed a baseline PAC-SYM score of 2.0±0.7, a sham response of –0.50±0.76, and a predicted SMS response of –0.80±0.76. Using a 2-sided, 2-sample equal-variance t-test with an α of 0.05, a sample size of 102 patients per arm would be required to achieve 80% power. As this was a pilot study, we instead aimed to enroll 20 patients per arm as a convenience sample for feasibility assessment [23].
Treatment protocol
A MagPro R30 Magnetic Stimulator (Medtronic) was used in this study. Treatments were delivered in the neurodiagnostic unit of a tertiary hospital at Singapore General Hospital. Patients were randomized by computer to either the SMS arm or the sham arm.
In the SMS arm, each patient underwent a 2-week stimulation period consisting of one 60-minute session daily. Each session comprised 30 minutes of thoracic nerve stimulation with the center of the coil positioned over the T9 spinous process and 30 minutes of lumbosacral nerve stimulation with the coil positioned over the L3 spinous process, with patients in the prone position. Stimulation intensity was set at 50% on the first day, 60% on the second day, and 70% on the remaining days. The stimulation frequency, burst length, and interval between interventions were fixed at 20 Hz, 2 seconds, and 28 seconds, respectively. The coil could heat up by a few degrees, to a maximum of 41 °C, and had a built-in safety mechanism that stopped stimulation automatically.
In the sham arm, a protocol similar to that used in the SMS arm was followed, except that the coil was angled vertically so that only its edge was in contact with the patient. In this configuration, no effective stimulation would be delivered because magnetic flux is maximal at the center of the coil.
Outcomes measured
The primary outcomes were symptom relief, safety, and tolerability of SMS, assessed using questionnaires. Patients’ medical information and Rome III diagnostic questionnaire data were analyzed. The primary questionnaire was the PAC-SYM [24]. It was administered at weeks 0, 1, and 2 and then every 2 weeks through week 14 after treatment or sham SMS. In addition, the EuroQOL 5-dimension instrument (EQ-5D) and the Hospital Anxiety and Depression Scale (HADS) were administered at the beginning of the study (weeks 0 and 2) and at the end of the study period (week 14). Both patients and assessors were blinded to the stimulation protocol.
Statistical analysis
Results were analyzed using R ver. 4.5.1 (R Foundation for Statistical Computing) statistical software. Baseline survey data between the treatment and sham arms were compared using the nonparametric Mann-Whitney U-test. Survey data over time within each arm were analyzed using the Skillings-Mack test. A P-value of <0.05 was considered statistically significant.
From December 2015 to July 2023, 19 patients were recruited. Recruitment was limited and was adversely affected by disruptions related to the COVID-19 pandemic. Three patients were excluded because they did not meet the inclusion/exclusion criteria or declined to participate. Of the remaining 16 patients, 8 were randomized to receive SMS and 8 were randomized to receive sham SMS. Two patients (25.0%) in the SMS arm did not complete the study for the following reasons: 1 withdrew on day 2 of treatment because of strong back muscle contractions, whereas the other withdrew during the COVID-19 pandemic after follow-up plans were disrupted. Compliance with treatment sessions and follow-up was complete among the remaining 14 patients (Fig. 1). The mean age was 55 years (range, 34–77 years), and 12 patients (85.7%) were male. Three patients had Parkinson disease, and 1 patient had spinal myelopathy (Table 1). Overall, patients tolerated the protocol well, with no significant adverse events. Although mild back contractions were reported, no clinically significant pain, neurological symptoms (twitching, numbness), or gastrointestinal symptoms (nausea, bloating) were observed in the remaining patients.
Baseline constipation symptoms and quality-of-life measures differed significantly between the groups. At baseline, the median number of bowel movements per week was 1.5 in the SMS arm and 4 in the sham arm (P=0.018) (Fig. 2). The median number of spontaneous bowel movements per week at baseline was not significantly different between the groups, at 0.3 in the SMS arm and 1 in the sham arm (P=0.130). The median EQ-5D health state score was significantly lower in the SMS arm than in the sham arm (50 vs. 72.5, P=0.026).
At 14 weeks from the start of treatment, patients in the SMS arm showed a trend toward improvement in 11 of the 16 PAC-SYM items. These included increases in the average number of bowel movements per week (1.5 to 3, 100% increase), the number of spontaneous bowel movements per week (0.3 to 1.3, 333% increase), and satisfaction with the regularity of bowel movements (Q2: 1 to 2, 100% increase), as well as decreases in incomplete bowel movements (Q9: 4 to 2, 50% decrease) and the sensation of needing to pass stool but being unable to do so (Q13: 3.5 to 1.5, 57.1% decrease). Patients in the sham arm also showed a trend toward improvement in 11 of the 16 PAC-SYM items, although the magnitude of improvement was smaller (Tables 2, 3). Similarly, EQ-5D health state scores increased more in the SMS arm, from 50 to 60, than in the sham arm, from 72.5 to 75, at 14 weeks. However, these improvements did not reach statistical significance across the 13 PAC-SYM questions assessed at weeks 1, 2, 4, 6, 8, 10, 12, and 14. Likewise, the EQ-5D (5 questions at weeks 0, 2, and 14) and HADS (14 questions at weeks 0, 2, and 14) questionnaires did not show a trend toward improvement in either arm.
Chronic functional constipation is a heterogeneous disorder with 3 subtypes: normal transit constipation, slow transit constipation, and defecatory disorders (e.g., anorectal anatomical abnormalities and pelvic dyssynergia) [25]. These classifications are based on colonic transit studies, dynamic defecography, and physiological testing. In practice, however, many patients present with mixed or overlapping features, which complicates treatment decisions and reduces the effectiveness of any single treatment modality.
The earliest studies using neuromodulation to treat functional constipation involved SNS, a technique well established in the management of fecal incontinence [26, 27]. The efficacy of SNS for constipation has been mixed, with earlier open-label studies reporting success rates of up to 85% [9], whereas subsequent randomized trials showed minimal benefit over sham treatment [7]. Most recently, Heemskerk et al. [28] showed in an open-label trial that sacral neuromodulation provided significant benefit compared with conservative treatment in patients with refractory idiopathic slow transit constipation. Nonetheless, a meta-analysis by the same group found considerable heterogeneity in study populations, definitions of functional constipation, and study designs, making it difficult to draw clear conclusions from the pooled data [10].
Compared with SNS, SMS represents a novel alternative neuromodulatory approach. First proposed in the late 1980s [29], SMS uses strong time-varying magnetic fields applied over the spine to induce electrical currents in neural tissues. SMS offers several advantages over SNS: it eliminates the need for electrode implantation and the associated risks of infection and device failure, thereby providing a potential noninvasive and painless approach to neuromodulation [19,20]. This technique has been studied in patients with spinal lesions or injury, movement disorders, muscle spasticity, neuropathic pain, and autonomic dysfunction [30–35]. Although its gastrointestinal applications remain experimental, physiological studies of SMS in the colon are encouraging. For example, Lin et al. [17] demonstrated increased rectal pressure and decreased colonic transit times using lumbosacral spinal and transabdominal functional magnetic stimulation.
To our knowledge, this is the only double-blind randomized controlled trial exploring the feasibility and therapeutic potential of SMS in patients with functional constipation refractory to conventional therapies. The trial was intended to be pragmatic in nature, reflecting real-world heterogeneity and effectiveness. The broad inclusion criteria allowed enrollment of an ethnically diverse population with a wide age range and comorbidities such as Parkinson disease and spinal myelopathy. We selected self-reported symptom questionnaires as the primary outcome measures to reflect patient symptom burden rather than relying on physiological parameters such as colonic transit time, defecography dynamics, and rectal pressure.
Our SMS protocol was adapted from previous work by Wang and Tsai [14], Chiu et al. [16], and Tsai et al. [21], who reported increased colonic transit times and improvement in symptoms. Whereas those studies used 10-minute stimulations at T9 and L3 for a total of 20 minutes twice daily for 3 weeks, we used 30-minute stimulations at T9 and L3 for a total of 60 minutes once daily for 2 weeks. Cumulatively, the total stimulation time was comparable, but in our study, it was delivered over a shorter 2-week period.
The trial demonstrated that the SMS technique was safe and relatively well tolerated. Only 1 patient withdrew because of significant discomfort. Otherwise, no adverse events were reported, and no clinically significant pain, neurological symptoms (twitching, numbness), or gastrointestinal symptoms (nausea, bloating) were observed.
Our findings showed a trend toward improvement in functional constipation symptoms in both arms, although the magnitude of improvement relative to baseline was greater in the SMS arm than in the sham arm. This included bowel movement frequency, satisfaction with bowel movements (PAC-SYM Q1, Q2), and perceived EQ-5D health state. For example, in the SMS arm, the median number of bowel movements increased from 1.5 to 3 per week (100% increase), and EQ-5D health state scores improved from 50 to 60 (20% increase) over the 14-week follow-up. In contrast, in the sham arm, the median number of bowel movements increased from 4 to 5 per week (25% increase), and EQ-5D health state scores increased from 72.5 to 75 (3% increase) over the same period. Among the PAC-SYM items, patients in the SMS arm showed the greatest improvement in Q13, which assessed the sensation of needing to pass a bowel movement but being unable to do so, at 14 weeks. Many patients (66.7%) reported this symptom as absent or mild at 14 weeks, compared with only 33% at baseline. However, these improvements did not reach statistical significance.
The trial faced several challenges. The results were limited by the small sample size, which reflected poor accrual and enrollment. The main barriers to participation included logistical difficulties in arranging daily hospital visits for 2 weeks, hesitancy related to the experimental nature of the study, and the commitment required for frequent questionnaire follow-up. Recruitment and follow-up were further constrained by the prolonged COVID-19 pandemic. Although participants and assessors were blinded to the study protocol, patients in the SMS arm naturally experienced greater muscle contractions than those in the sham arm, which may have affected the effectiveness of blinding.
In our study population, although functional constipation is more prevalent in women, the cohort was predominantly male. This may reflect selection bias related to tertiary-center referral patterns or willingness to participate in an interventional study. Given the small sample size inherent to this pilot trial, these factors may have amplified the sex imbalance.
There was considerable heterogeneity in PAC-SYM responses between the SMS and sham arms. For example, the baseline median number of bowel movements was 1.5 (range, 1–3) in the SMS arm and 4 (range, 1–7) in the sham arm, reflecting differences in constipation severity between the groups. Although the trial excluded patients with significant defecatory disorders, not all patients underwent comprehensive pelvic floor functional testing before study enrollment. Seven of the 14 patients had functional defecatory imaging findings of a small rectocele. It is possible that these patients had mixed subtypes of chronic functional constipation, with varying contributions from defecatory and transit disorders, thereby increasing study heterogeneity.
Although the Rome III criteria for functional constipation are well established, numerous constipation assessment tools have been described in the literature, each with its own strengths and limitations [36]. We selected the PAC-SYM questionnaire because it has been well validated and has high internal consistency and test-retest reliability [24, 37]. Nonetheless, despite their clinical utility, self-reported questionnaires remain vulnerable to recall bias and subjective interpretation. In addition, our follow-up period was relatively short, at 14 weeks after treatment.
Collectively, these factors highlight the challenges, heterogeneity, and limitations inherent in conducting a pragmatic pilot trial in patients with functional constipation.
Although our trial results are inconclusive, it is notable that none of the 6 patients in the SMS arm remain on long-term follow-up seeking further treatment for chronic constipation. In contrast, 2 of the 8 patients in the sham arm remain on follow-up for constipation at present. Although anecdotal, this observation may reflect a real-world benefit of SMS.
When compared with existing studies of SMS for constipation, the findings of Wang and Tsai [14], Chiu et al. [16], and Tsai et al. [21] showed statistically significant improvement in self-reported outcomes on the Knowles-Eccersley-Scott Symptom Score (KESS), including frequency of bowel movements, time required for evacuation, and difficult or unsuccessful evacuations, for up to 3 months after SMS. These studies examined specific patient subgroups, including patients with Parkinson disease, spinal cord injury, and older adults. Baseline bowel movement frequency in those studies was similar to that in the SMS arm of our study, with most patients reporting 1 to 2 bowel movements per week at baseline. In those studies, SMS showed no effect in patients with spinal cord injury, decreased efficacy in older adults, and increased bowel movement frequency in patients with Parkinson disease. Taken together, these findings suggest that certain patient subgroups may respond better to SMS than others, whereas older adults may derive less benefit. Nonetheless, these were open-label trials and were therefore susceptible to observer, performance, and detection bias.
Conclusions
SMS appears to be safe and feasible. Although patients who received SMS reported improvement in constipation symptoms, the results did not reach statistical significance, likely because of the small sample size. Further studies with larger sample sizes, protocol optimization, and possibly stratification by selected subgroups are needed to improve understanding of SMS and to evaluate its role as a noninvasive therapeutic option for chronic constipation.

Conflict of interest

Emile John Kwong Wei Tan is an editorial board member of this journal, but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: YLL, EJKWT; Data curation: TSQL, YLL, PPCT, YET; Formal analysis: TSQL, KXY; Investigation: TSQL; Methodology: all authors; Project administration: TSQL, YLL, PPCT, YET, EJKWT; Supervision: TSQL, YLL, EJKWT; Validation: TSQL; Visualization: TSQL; Writing–original draft: TSQL; Writing–review & editing: all authors. All authors read and approved the final manuscript.

Fig. 1.
Flow diagram of patient recruitment, randomization, and follow-up. SMS, spinal magnetic stimulation.
ac-2025-01599-0228f1.jpg
Fig. 2.
Median bowel movements over time in the spinal magnetic stimulation (SMS) and sham arms.
ac-2025-01599-0228f2.jpg
Table 1.
Baseline patient characteristics (n=14)
Characteristic SMS arm (n=6) Sham arm (n=8)
Age (yr) 54 (41–69) 55.5 (34–77)
Male sex 5 (83.3) 7 (87.5)
Ethnicity
 Chinese 5 (83.3) 5 (62.5)
 Malay 0 (0) 1 (12.5)
 Indian 0 (0) 1 (12.5)
 Other 1 (16.7) 1 (12.5)
Married 4 (66.7) 7 (87.5)
Employed or working 4 (66.7) 4 (50.0)
Educational level
 Degree or higher qualification 3 (50.0) 3 (37.5)
 Diploma 2 (33.3) 2 (25.0)
 Primary or secondary school 1 (16.7) 3 (37.5)
Received prior biofeedback therapy 3 (50.0) 4 (50.0)
History of solitary rectal ulcer syndrome or proctitis 1 (16.7) 3 (37.5)
Small or minor rectocele on MRI defecography 3 (50.0) 4 (50.0)
Previous pelvic floor surgery 0 (0) 1 (12.5)
Associated condition
 Parkinson disease 1 (16.7) 2 (25.0)
 Spinal disease 1 (16.7) 0 (0)

Values are presented as median (range) or number (%).

SMS, spinal magnetic stimulation; MRI, magnetic resonance imaging.

Table 2.
Questionnaire scores in the SMS and sham arms at baseline and week 14
Item SMS arm Sham arm
Week 0 (baseline) Week 14 P-value Week 0 (baseline) Week 14 P-value
PAC-SYM questionnaire
 No. of bowel movements per weeka 1.5 (1.0–2.8) 3.0 (1.1–6.4) 0.233 4.0 (3.8–5.0) 5.0 (3.5–8.0) 0.437
 No. of spontaneous bowel movements per weekb 0.3 (0–0.9) 1.3 (0.3–3.8) 0.750 1.0 (0–3.5) 2.0 (0.8–4.5) 0.808
 No. of spontaneous complete bowel movements per week 0 (0–0) 0 (0–0.8) 0.720 0 (0–1.0) 0 (0–1.0) 0.991
 Q1. Have you been satisfied with how often you have a bowel movement? 1.0 (1.0–1.8) 2.5 (2.0–3.0) 0.767 2.5 (2.0–3.0) 3.0 (1.5–4.0) 0.989
 Q2. Have you been satisfied with the regularity of your bowel movements? 1.0 (1.0–1.0) 2.0 (2.0–3.0) 0.736 2.0 (1.0–3.0) 3.0 (1.5–3.5) 0.897
 Q3. Have you been satisfied with the time it takes for food to pass through the intestines? 2.0 (1.0–3.0) 2.0 (2.0–2.8) 0.974 3.0 (2.5–3.3) 3.0 (2.0–3.0) 0.764
 Q4. Have you been satisfied with your treatment? 3.0 (3.0–3.0) 2.5 (2.0–3.0) 0.970 1.0 (1.0–4.0) 2.0 (1.5–2.5) 0.965
 Q5. Discomfort in your stomach 2.5 (1.3–3.0) 3.0 (1.5–3.0) 0.960 2.5 (1.8–3.0) 3.0 (2.0–3.0) 0.714
 Q6. Pain in your stomach 2.0 (1.3–2.0) 1.5 (1.0–2.8) >0.999 1.0 (1.0–1.3) 2.0 (1.0–2.5) 0.535
 Q7. Bloating in your stomach 2.5 (2.0–3.8) 3.0 (2.3–3.0) 0.936 2.5 (1.8–3.0) 2.0 (1.0–3.0) 0.792
 Q8. Stomach cramps 1.5 (1.0–2.0) 1.5 (1.0–2.8) 0.932 1.0 (1.0–1.3) 1.0 (1.0–2.5) 0.801
 Q9. Incomplete bowel movement 4.0 (3.3–4.0) 2.0 (2.0–3.5) 0.240 3.5 (2.8–4.3) 3.0 (2.0–3.0) 0.787
 Q10. Stools were too hard 3.0 (3.0–3.8) 2.0 (2.0–2.8) 0.453 3.5 (1.8–4.3) 2.0 (1.5–2.5) >0.999
 Q11. Stools were too small 3.5 (2.3–4.0) 2.5 (2.0–3.8) 0.965 2.5 (1.0–4.3) 2.0 (1.0–3.0) 0.470
 Q12. Straining or squeezing to try to pass stools 3.0 (2.3–4.5) 2.5 (2.0–3.0) 0.945 4.0 (3.5–5.0) 3.0 (2.0–4.0) 0.891
 Q13. Feeling like you had to pass a stool but you could not 3.5 (2.3–4.8) 1.5 (1.0–2.8) 0.078 3.5 (2.8–4.0) 2.0 (2.0–2.5) 0.217
EQ-5D
 Q1. Mobility 0 (0–0.8) 0 (0–0.8) 0.861 0 (0–0.3) 0 (0–0.0) 0.946
 Q2. Self-care 0 (0–0) 0 (0–0) >0.999 0 (0–0.3) 0 (0–0) 0.946
 Q3. Usual activities 1.0 (0.3–1.0) 0.5 (0–1.0) 0.872 0.5 (0–1.0) 0 (0–0.5) 0.711
 Q4. Pain/discomfort 1.0 (1.0–1.0) 1.0 (0.3–1.0) 0.958 1.0 (0.0–1.0) 1.0 (0.5–1.0) 0.597
 Q5. Anxiety/depression 1.0 (0.3–1.0) 1.0 (0.3–1.0) 0.861 1 (0–1.0) 0 (0–1.0) 0.505
 Health state score 50.0 (49.3–50.0) 60.0 (50.0–75.0) 0.176 72.5 (60.0–81.3) 75.0 (70.0–82.5) 0.521
HADS questionnaire
 Q1. I feel tense or “wound up” 1.0 (0.3–1.8) 1.0 (0–1.0) 0.710 1.0 (0.8–1.3) 1.0 (0.8–1.0) >0.999
 Q2. I still enjoy the things I used to enjoy 1.0 (0.3–1.8) 1.0 (1.0–1.0) 0.370 1.0 (0.8–1.0) 0.5 (0.0–1.0) 0.597
 Q3. I get a sort of frightened feeling as if something awful is about to happen 0.5 (0–1.0) 1.0 (0–2.0) 0.812 1.0 (1.0–1.3) 1.0 (0.8–1.0) 0.869
 Q4. I can laugh and see the funny side of things 1.0 (0.3–1.0) 1.0 (1.0–1.0) 0.872 0.5 (0–1.0) 0.5 (0–1.3) 0.944
 Q5. Worrying thoughts go through my mind 1.0 (0.3–1.0) 1.0 (0–1.0) 0.672 1.0 (0–1.0) 0 (0–0.3) 0.784
 Q6. I feel cheerful 0.5 (0–1.0) 1.0 (1.0–1.0) 0.872 0 (0–0.3) 0 (0–0) 0.287
 Q7. I can sit at ease and feel relaxed 1.0 (0.3–1.0) 1.0 (1.0–1.0) 0.958 1.0 (0.8–1.0) 0.5 (0–1.3) 0.585
 Q8. I feel as if I am slowed down 2.0 (0.5–2.0) 2.0 (0–2.0) 0.706 1.0 (1.0–1.3) 1.0 (0.8–1.3) 0.869
 Q9. I get a sort of frightened feeling like “butterflies” in the stomach 0 (0–0.8) 1.0 (0–1.0) 0.943 0.5 (0–1.0) 0.5 (0–1.0) 0.597
 Q10. I have lost interest in my appearance 1.5 (1.0–2.0) 1.0 (1.0–2.0) 0.834 1.5 (1.0–2.0) 1.0 (0.8–1.0) 0.869
 Q11. I feel restless as if I have to be on the move 1.0 (0.3–1.0) 1.0 (0–2.0) 0.467 0.5 (0–1.3) 0 (0–0.3) 0.597
 Q12. I look forward with enjoyment to things 1.5 (0.3–2.0) 1.0 (0–2.0) 0.706 1.0 (1.0–1.3) 0.5 (0–1.3) 0.711
 Q13. I get sudden feelings of panic 2.0 (1.3–2.0) 1.0 (1.0–2.0) 0.943 1.5 (0.8–3.0) 1.0 (1.0–1.5) 0.949
 Q14. I can enjoy a good book or radio or television programme 1.0 (0.3–1.8) 1.0 (0–1.0) 0.834 1.0 (0.8–1.3) 0 (0–0) 0.869

Values are presented as median (interquartile range).

SMS, spinal magnetic stimulation; PAC-SYM, Patient Assessment of Constipation Symptoms; EQ-5D, EuroQOL 5-dimension instrument; HADS, Hospital Anxiety and Depression Scale.

aThe total number of bowel movements per week, with or without the use of laxatives. bThe number of bowel movements per week passed without the use of laxatives.

Table 3.
Percentage changes in median questionnaire scores in the SMS and sham arms from baseline to week 14
Item SMS arm Sham arm
% Change P-value % Change P-value
PAC-SYM questionnaire
 No. of bowel movements per weeka 100 0.233 25.0 0.437
 No. of spontaneous bowel movements per weekb 333.3 0.750 100 0.808
 No. of spontaneous complete bowel movements per week 0 0.720 0 0.991
 Q1. Have you been satisfied with how often you have a bowel movement? 150 0.767 20.0 0.989
 Q2. Have you been satisfied with the regularity of your bowel movements? 100 0.736 50.0 0.897
 Q3. Have you been satisfied with the time it takes for food to pass through the intestines? 0 0.974 0 0.764
 Q4. Have you been satisfied with your treatment? –16.7 0.970 100 0.965
 Q5. Discomfort in your stomach 20.0 0.960 20.0 0.714
 Q6. Pain in your stomach –25.0 >0.999 100 0.535
 Q7. Bloating in your stomach 20.0 0.936 –20.0 0.792
 Q8. Stomach cramps 0 0.932 0 0.801
 Q9. Incomplete bowel movement –50.0 0.240 –14.3 0.787
 Q10. Stools were too hard –33.3 0.453 –42.9 >0.999
 Q11. Stools were too small –28.6 0.965 –20.0 0.470
 Q12. Straining or squeezing to try to pass stools –16.7 0.940 –25.0 0.891
 Q13. Feeling like you had to pass a stool but you could not –57.1 0.078 –42.9 0.217
EQ-5D health state score 20.0 0.176 3.4 0.521

SMS, spinal magnetic stimulation; PAC-SYM, Patient Assessment of Constipation Symptoms; EQ-5D, EuroQOL 5-dimension instrument.

aThe total number of bowel movements per week, with or without the use of laxatives. bThe number of bowel movements per week passed without the use of laxatives.

  • 1. Wald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Helfrich I, Schuijt C, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007;26:227–36. ArticlePubMed
  • 2. Ihara E, Manabe N, Ohkubo H, Ogasawara N, Ogino H, Kakimoto K, et al. Evidence-based clinical guidelines for chronic constipation 2023. Digestion 2025;106:62–89. ArticlePDF
  • 3. Chang L, Chey WD, Imdad A, Almario CV, Bharucha AE, Diem S, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. Am J Gastroenterol 2023;118:936–54. ArticlePubMedPMC
  • 4. Tomita T, Kazumori K, Baba K, Zhao X, Chen Y, Miwa H. Impact of chronic constipation on health-related quality of life and work productivity in Japan. J Gastroenterol Hepatol 2021;36:1529–37. ArticlePubMedPDF
  • 5. Nyam DC, Pemberton JH, Ilstrup DM, Rath DM. Long-term results of surgery for chronic constipation. Dis Colon Rectum 1997;40:273–9. ArticlePubMed
  • 6. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, et al. Low-dose linaclotide (72 mg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2018;113:105–14. ArticlePubMed
  • 7. Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve stimulation for faecal incontinence and constipation in adults. Cochrane Database Syst Rev 2015;2015:CD004464.ArticlePubMedPMC
  • 8. Dinning PG, Hunt L, Patton V, Zhang T, Szczesniak M, Gebski V, et al. Treatment efficacy of sacral nerve stimulation in slow transit constipation: a two-phase, double-blind randomized controlled crossover study. Am J Gastroenterol 2015;110:733–40. ArticlePubMedPDF
  • 9. Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. Br J Surg 2013;100:174–81. ArticlePubMedPDF
  • 10. Heemskerk SC, van der Wilt AA, Penninx BM, Kleijnen J, Melenhorst J, Dirksen CD, et al. Effectiveness, safety and cost-effectiveness of sacral neuromodulation for idiopathic slow-transit constipation: a systematic review. Colorectal Dis 2024;26:417–27. ArticlePubMed
  • 11. Carrington EV, Knowles CH. The influence of sacral nerve stimulation on anorectal dysfunction. Colorectal Dis 2011;13 Suppl 2:5–9. ArticlePubMed
  • 12. Li G, Jin B, Fan Z. Clinical application of transcranial magnetic stimulation for functional bowel disease. Front Med (Lausanne) 2023;10:1213067.ArticlePubMedPMC
  • 13. Yun YC, Yoon YS, Kim ES, Lee YJ, Lee JG, Jo WJ, et al. Transabdominal functional magnetic stimulation for the treatment of constipation in brain-injured patients: a randomized controlled trial. Ann Rehabil Med 2019;43:19–26. ArticlePubMedPMCPDF
  • 14. Wang CP, Tsai PY. Efficacy of spinal magnetic stimulation in elderly persons with chronic constipation. J Chin Med Assoc 2012;75:127–31. ArticlePubMed
  • 15. Lee KJ, Kim JH, Cho SW. Short-term effects of magnetic sacral dermatome stimulation for idiopathic slow transit constipation: sham-controlled, cross-over pilot study. J Gastroenterol Hepatol 2006;21(1 Pt 1):47–53. ArticlePubMed
  • 16. Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson's disease. J Rehabil Med 2009;41:1085–9. ArticlePubMed
  • 17. Lin VW, Nino-Murcia M, Frost F, Wolfe V, Hsiao I, Perkash I. Functional magnetic stimulation of the colon in persons with spinal cord injury. Arch Phys Med Rehabil 2001;82:167–73. ArticlePubMed
  • 18. Beaulieu LD, Schneider C. Effects of repetitive peripheral magnetic stimulation on normal or impaired motor control. A review. Neurophysiol Clin 2013;43:251–60. ArticlePubMed
  • 19. Barker AT. An introduction to the basic principles of magnetic nerve stimulation. J Clin Neurophysiol 1991;8:26–37. ArticlePubMed
  • 20. Kanjanapanang N, Chang KV. Peripheral magnetic stimulation. In: StatPearls [Internet]. StatPearls Publishing; [updated 2022 Oct 31; cited 2025 Jul 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526087/
  • 21. Tsai PY, Wang CP, Chiu FY, Tsai YA, Chang YC, Chuang TY. Efficacy of functional magnetic stimulation in neurogenic bowel dysfunction after spinal cord injury. J Rehabil Med 2009;41:41–7. ArticlePubMed
  • 22. Piessevaux H, Corazziari E, Rey E, Simren M, Wiechowska-Kozlowska A, Kerstens R, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil 2015;27:805–15. ArticlePubMedPDF
  • 23. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health 2008;31:180–91. ArticlePubMedPMC
  • 24. Neri L, Conway PM, Basilisco G; Laxative Inadequate Relief Survey (LIRS) Group. Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. Qual Life Res 2015;24:1597–605. ArticlePubMedPDF
  • 25. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology 2013;144:211–7. ArticlePubMed
  • 26. Eggers E, Crouss T, Beausang J, Smith D, Spector S, Saracco B, et al. Long-term outcomes of sacral nerve stimulation on the treatment of fecal incontinence: a systematic review. Neuromodulation 2025;28:715–26. ArticlePubMed
  • 27. van Ophoven A, Engelberg S, Lilley H, Sievert KD. Systematic literature review and meta-analysis of sacral neuromodulation (SNM) in patients with neurogenic lower urinary tract dysfunction (nLUTD): over 20 years' experience and future directions. Adv Ther 2021;38:1987–2006. ArticlePubMedPMCPDF
  • 28. Heemskerk SC, Dirksen CD, van Kuijk SM, Benninga MA, Baeten CI, Masclee AA, et al. Sacral neuromodulation versus conservative treatment for refractory idiopathic slow-transit constipation: the randomized clinical no.2-trial. Ann Surg 2024;279:746–54. ArticlePubMed
  • 29. Barker AT, Freeston IL, Jalinous R, Jarratt JA. Magnetic stimulation of the human brain and peripheral nervous system: an introduction and the results of an initial clinical evaluation. Neurosurgery 1987;20:100–9. ArticlePubMed
  • 30. Chalfouh C, Guillou C, Hardouin J, Delarue Q, Li X, Duclos C, et al. The regenerative effect of trans-spinal magnetic stimulation after spinal cord injury: mechanisms and pathways underlying the effect. Neurotherapeutics 2020;17:2069–88. ArticlePubMedPMCPDF
  • 31. Hachmann JT, Yousak A, Wallner JJ, Gad PN, Edgerton VR, Gorgey AS. Epidural spinal cord stimulation as an intervention for motor recovery after motor complete spinal cord injury. J Neurophysiol 2021;126:1843–59. ArticlePubMed
  • 32. Cai Y, Reddy RD, Varshney V, Chakravarthy KV. Spinal cord stimulation in Parkinson's disease: a review of the preclinical and clinical data and future prospects. Bioelectron Med 2020;6:5.ArticlePubMedPMCPDF
  • 33. Carra RB, Silva GD, Paraguay IB, Diniz de Lima F, Menezes JR, Pineda AM, et al. Controversies and clinical applications of non-invasive transspinal magnetic stimulation: a critical review and exploratory trial in hereditary spastic paraplegia. J Clin Med 2022;11:4748.ArticlePubMedPMC
  • 34. Lim YH, Song JM, Choi EH, Lee JW. Effects of repetitive peripheral magnetic stimulation on patients with acute low back pain: a pilot study. Ann Rehabil Med 2018;42:229–38. ArticlePubMedPMCPDF
  • 35. Niu T, Bennett CJ, Keller TL, Leiter JC, Lu DC. A proof-of-concept study of transcutaneous magnetic spinal cord stimulation for neurogenic bladder. Sci Rep 2018;8:12549.ArticlePubMedPMCPDF
  • 36. Coffin B, Caussé C. Constipation assessment scales in adults: a literature review including the new Bowel Function Index. Expert Rev Gastroenterol Hepatol 2011;5:601–13. ArticlePubMed
  • 37. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209–17. ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Feasibility and preliminary outcomes of spinal magnetic stimulation for functional constipation: a pilot randomized placebo-controlled trial
        Ann Coloproctol. 2026;42(4):415-424.   Published online August 25, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      Related articles
      Feasibility and preliminary outcomes of spinal magnetic stimulation for functional constipation: a pilot randomized placebo-controlled trial
      Image Image
      Fig. 1. Flow diagram of patient recruitment, randomization, and follow-up. SMS, spinal magnetic stimulation.
      Fig. 2. Median bowel movements over time in the spinal magnetic stimulation (SMS) and sham arms.
      Feasibility and preliminary outcomes of spinal magnetic stimulation for functional constipation: a pilot randomized placebo-controlled trial
      Characteristic SMS arm (n=6) Sham arm (n=8)
      Age (yr) 54 (41–69) 55.5 (34–77)
      Male sex 5 (83.3) 7 (87.5)
      Ethnicity
       Chinese 5 (83.3) 5 (62.5)
       Malay 0 (0) 1 (12.5)
       Indian 0 (0) 1 (12.5)
       Other 1 (16.7) 1 (12.5)
      Married 4 (66.7) 7 (87.5)
      Employed or working 4 (66.7) 4 (50.0)
      Educational level
       Degree or higher qualification 3 (50.0) 3 (37.5)
       Diploma 2 (33.3) 2 (25.0)
       Primary or secondary school 1 (16.7) 3 (37.5)
      Received prior biofeedback therapy 3 (50.0) 4 (50.0)
      History of solitary rectal ulcer syndrome or proctitis 1 (16.7) 3 (37.5)
      Small or minor rectocele on MRI defecography 3 (50.0) 4 (50.0)
      Previous pelvic floor surgery 0 (0) 1 (12.5)
      Associated condition
       Parkinson disease 1 (16.7) 2 (25.0)
       Spinal disease 1 (16.7) 0 (0)
      Item SMS arm Sham arm
      Week 0 (baseline) Week 14 P-value Week 0 (baseline) Week 14 P-value
      PAC-SYM questionnaire
       No. of bowel movements per weeka 1.5 (1.0–2.8) 3.0 (1.1–6.4) 0.233 4.0 (3.8–5.0) 5.0 (3.5–8.0) 0.437
       No. of spontaneous bowel movements per weekb 0.3 (0–0.9) 1.3 (0.3–3.8) 0.750 1.0 (0–3.5) 2.0 (0.8–4.5) 0.808
       No. of spontaneous complete bowel movements per week 0 (0–0) 0 (0–0.8) 0.720 0 (0–1.0) 0 (0–1.0) 0.991
       Q1. Have you been satisfied with how often you have a bowel movement? 1.0 (1.0–1.8) 2.5 (2.0–3.0) 0.767 2.5 (2.0–3.0) 3.0 (1.5–4.0) 0.989
       Q2. Have you been satisfied with the regularity of your bowel movements? 1.0 (1.0–1.0) 2.0 (2.0–3.0) 0.736 2.0 (1.0–3.0) 3.0 (1.5–3.5) 0.897
       Q3. Have you been satisfied with the time it takes for food to pass through the intestines? 2.0 (1.0–3.0) 2.0 (2.0–2.8) 0.974 3.0 (2.5–3.3) 3.0 (2.0–3.0) 0.764
       Q4. Have you been satisfied with your treatment? 3.0 (3.0–3.0) 2.5 (2.0–3.0) 0.970 1.0 (1.0–4.0) 2.0 (1.5–2.5) 0.965
       Q5. Discomfort in your stomach 2.5 (1.3–3.0) 3.0 (1.5–3.0) 0.960 2.5 (1.8–3.0) 3.0 (2.0–3.0) 0.714
       Q6. Pain in your stomach 2.0 (1.3–2.0) 1.5 (1.0–2.8) >0.999 1.0 (1.0–1.3) 2.0 (1.0–2.5) 0.535
       Q7. Bloating in your stomach 2.5 (2.0–3.8) 3.0 (2.3–3.0) 0.936 2.5 (1.8–3.0) 2.0 (1.0–3.0) 0.792
       Q8. Stomach cramps 1.5 (1.0–2.0) 1.5 (1.0–2.8) 0.932 1.0 (1.0–1.3) 1.0 (1.0–2.5) 0.801
       Q9. Incomplete bowel movement 4.0 (3.3–4.0) 2.0 (2.0–3.5) 0.240 3.5 (2.8–4.3) 3.0 (2.0–3.0) 0.787
       Q10. Stools were too hard 3.0 (3.0–3.8) 2.0 (2.0–2.8) 0.453 3.5 (1.8–4.3) 2.0 (1.5–2.5) >0.999
       Q11. Stools were too small 3.5 (2.3–4.0) 2.5 (2.0–3.8) 0.965 2.5 (1.0–4.3) 2.0 (1.0–3.0) 0.470
       Q12. Straining or squeezing to try to pass stools 3.0 (2.3–4.5) 2.5 (2.0–3.0) 0.945 4.0 (3.5–5.0) 3.0 (2.0–4.0) 0.891
       Q13. Feeling like you had to pass a stool but you could not 3.5 (2.3–4.8) 1.5 (1.0–2.8) 0.078 3.5 (2.8–4.0) 2.0 (2.0–2.5) 0.217
      EQ-5D
       Q1. Mobility 0 (0–0.8) 0 (0–0.8) 0.861 0 (0–0.3) 0 (0–0.0) 0.946
       Q2. Self-care 0 (0–0) 0 (0–0) >0.999 0 (0–0.3) 0 (0–0) 0.946
       Q3. Usual activities 1.0 (0.3–1.0) 0.5 (0–1.0) 0.872 0.5 (0–1.0) 0 (0–0.5) 0.711
       Q4. Pain/discomfort 1.0 (1.0–1.0) 1.0 (0.3–1.0) 0.958 1.0 (0.0–1.0) 1.0 (0.5–1.0) 0.597
       Q5. Anxiety/depression 1.0 (0.3–1.0) 1.0 (0.3–1.0) 0.861 1 (0–1.0) 0 (0–1.0) 0.505
       Health state score 50.0 (49.3–50.0) 60.0 (50.0–75.0) 0.176 72.5 (60.0–81.3) 75.0 (70.0–82.5) 0.521
      HADS questionnaire
       Q1. I feel tense or “wound up” 1.0 (0.3–1.8) 1.0 (0–1.0) 0.710 1.0 (0.8–1.3) 1.0 (0.8–1.0) >0.999
       Q2. I still enjoy the things I used to enjoy 1.0 (0.3–1.8) 1.0 (1.0–1.0) 0.370 1.0 (0.8–1.0) 0.5 (0.0–1.0) 0.597
       Q3. I get a sort of frightened feeling as if something awful is about to happen 0.5 (0–1.0) 1.0 (0–2.0) 0.812 1.0 (1.0–1.3) 1.0 (0.8–1.0) 0.869
       Q4. I can laugh and see the funny side of things 1.0 (0.3–1.0) 1.0 (1.0–1.0) 0.872 0.5 (0–1.0) 0.5 (0–1.3) 0.944
       Q5. Worrying thoughts go through my mind 1.0 (0.3–1.0) 1.0 (0–1.0) 0.672 1.0 (0–1.0) 0 (0–0.3) 0.784
       Q6. I feel cheerful 0.5 (0–1.0) 1.0 (1.0–1.0) 0.872 0 (0–0.3) 0 (0–0) 0.287
       Q7. I can sit at ease and feel relaxed 1.0 (0.3–1.0) 1.0 (1.0–1.0) 0.958 1.0 (0.8–1.0) 0.5 (0–1.3) 0.585
       Q8. I feel as if I am slowed down 2.0 (0.5–2.0) 2.0 (0–2.0) 0.706 1.0 (1.0–1.3) 1.0 (0.8–1.3) 0.869
       Q9. I get a sort of frightened feeling like “butterflies” in the stomach 0 (0–0.8) 1.0 (0–1.0) 0.943 0.5 (0–1.0) 0.5 (0–1.0) 0.597
       Q10. I have lost interest in my appearance 1.5 (1.0–2.0) 1.0 (1.0–2.0) 0.834 1.5 (1.0–2.0) 1.0 (0.8–1.0) 0.869
       Q11. I feel restless as if I have to be on the move 1.0 (0.3–1.0) 1.0 (0–2.0) 0.467 0.5 (0–1.3) 0 (0–0.3) 0.597
       Q12. I look forward with enjoyment to things 1.5 (0.3–2.0) 1.0 (0–2.0) 0.706 1.0 (1.0–1.3) 0.5 (0–1.3) 0.711
       Q13. I get sudden feelings of panic 2.0 (1.3–2.0) 1.0 (1.0–2.0) 0.943 1.5 (0.8–3.0) 1.0 (1.0–1.5) 0.949
       Q14. I can enjoy a good book or radio or television programme 1.0 (0.3–1.8) 1.0 (0–1.0) 0.834 1.0 (0.8–1.3) 0 (0–0) 0.869
      Item SMS arm Sham arm
      % Change P-value % Change P-value
      PAC-SYM questionnaire
       No. of bowel movements per weeka 100 0.233 25.0 0.437
       No. of spontaneous bowel movements per weekb 333.3 0.750 100 0.808
       No. of spontaneous complete bowel movements per week 0 0.720 0 0.991
       Q1. Have you been satisfied with how often you have a bowel movement? 150 0.767 20.0 0.989
       Q2. Have you been satisfied with the regularity of your bowel movements? 100 0.736 50.0 0.897
       Q3. Have you been satisfied with the time it takes for food to pass through the intestines? 0 0.974 0 0.764
       Q4. Have you been satisfied with your treatment? –16.7 0.970 100 0.965
       Q5. Discomfort in your stomach 20.0 0.960 20.0 0.714
       Q6. Pain in your stomach –25.0 >0.999 100 0.535
       Q7. Bloating in your stomach 20.0 0.936 –20.0 0.792
       Q8. Stomach cramps 0 0.932 0 0.801
       Q9. Incomplete bowel movement –50.0 0.240 –14.3 0.787
       Q10. Stools were too hard –33.3 0.453 –42.9 >0.999
       Q11. Stools were too small –28.6 0.965 –20.0 0.470
       Q12. Straining or squeezing to try to pass stools –16.7 0.940 –25.0 0.891
       Q13. Feeling like you had to pass a stool but you could not –57.1 0.078 –42.9 0.217
      EQ-5D health state score 20.0 0.176 3.4 0.521
      Table 1. Baseline patient characteristics (n=14)

      Values are presented as median (range) or number (%).

      SMS, spinal magnetic stimulation; MRI, magnetic resonance imaging.

      Table 2. Questionnaire scores in the SMS and sham arms at baseline and week 14

      Values are presented as median (interquartile range).

      SMS, spinal magnetic stimulation; PAC-SYM, Patient Assessment of Constipation Symptoms; EQ-5D, EuroQOL 5-dimension instrument; HADS, Hospital Anxiety and Depression Scale.

      aThe total number of bowel movements per week, with or without the use of laxatives. bThe number of bowel movements per week passed without the use of laxatives.

      Table 3. Percentage changes in median questionnaire scores in the SMS and sham arms from baseline to week 14

      SMS, spinal magnetic stimulation; PAC-SYM, Patient Assessment of Constipation Symptoms; EQ-5D, EuroQOL 5-dimension instrument.

      aThe total number of bowel movements per week, with or without the use of laxatives. bThe number of bowel movements per week passed without the use of laxatives.


      Ann Coloproctol : Annals of Coloproctology Twitter Facebook
      TOP